On March 3, 2021 Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, reported that company executives will participate in three investor conferences in March 2021 (Press release, Sierra Oncology, MAR 3, 2021, View Source [SID1234575987]). Stephen Dilly, MBBS, PhD, Chief Executive Officer of Sierra will provide a company update at the HC Wainwright Life Sciences Conference and the Oppenheimer Healthcare Conference; Barbara Klencke, MD, Chief Development Officer will participate in a panel discussion at the 33rd Annual Roth Conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:

Conference:

HC Wainwright Global Life Sciences Conference

Presenter:

Stephen Dilly, MBBS, PhD, Chief Executive Officer

Date:

Tuesday, March 9, 2021

Time:

On Demand Viewing starting at 7:00 am ET

Conference:

Virtual 33rd Annual Roth Conference

Presenter:

Barbara Klencke, MD, Chief Development Officer

Session:

Large Market Opportunities in RARE Hematologic & Inflammatory Disease

Date:

Monday, March 15, 2021

Time:

10:00 am – 11:00 am ET

Conference:

Oppenheimer 31st Annual Healthcare Conference

Presenter:

Stephen Dilly, MBBS, PhD, Chief Executive Officer

Date:

Wednesday, March 17, 2021

Time:

1:50 pm – 2:20 pm ET

All three presentations will be webcast and available at the times noted above on the Investors section of Sierra’s corporate website in the Events & Webcast tab.